| Literature DB >> 30515397 |
Gang Liu1, Laidi Ding1, Bo Han1, Sofie Piepers2, S Ali Naqvi3, Herman W Barkema2,3, Tariq Ali1, Sarne De Vliegher2, Siyu Xu1, Jian Gao1.
Abstract
Escherichia coli is a major udder pathogen causing clinical mastitis in dairy cattle and its heat stable endotoxin in powdered infant formula milk is a potential risk factor in neonatal infections. Cephalosporins are frequently used for treatment of mastitis caused by mastitis; however, use of these antimicrobials may induce antimicrobial resistance in E. coli. The objective of this study was to explore the in vitro effect of subminimum inhibitory concentrations (sub-MIC) of cefalotin (CF) and ceftazidime (CAZ) on the morphology, antimicrobial resistance, and endotoxin releasing characteristics of 3 E. coli isolates recovered from bovine clinical mastitis. The parent E. coli isolates, which were susceptible to CF and CAZ, were exposed to CF or CAZ separately at sub-MIC levels to produce 9 generations of induced isolates. Colonies of the CAZ-induced isolates from all 3 parent E. coli were smaller on blood agar and the bacteria became filamentous, whereas the CF-induced isolates did not demonstrate prominent morphological changes. After induction by CF or CAZ, many induced isolates showed resistance to cefoxitin, CAZ, CF, kanamycin, ampicillin, and amoxicillin/clavulanic acid while their parent isolates were susceptible to these antimicrobials. Notably, 5 CAZ-induced isolates from the same parent isolate were found to produce extended-spectrum beta-lactamase (ESBL) though none of the tested ESBL related genes could be detected. All CAZ-induced isolates released more endotoxin with a higher release rate, whereas endotoxin release of CF-induced E. coli isolates was not different from parent isolates. The exposure of cephalosporins at sub-MIC levels induced resistant Escherichia coli. We inferred that cephalosporins, especially CAZ, should be used prudently for treatment of clinical E. coli mastitis.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30515397 PMCID: PMC6236695 DOI: 10.1155/2018/4301628
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Primers used to detect extended spectrum beta-lactamase encoding genes.
| Genes | Primer sequence (5′ to 3′) | Amplicon size (bp) |
|---|---|---|
| | CGC TTT GCG ATG TGC AG | 550 |
| ACC GCG ATA TCG TTG GT | ||
|
| GTT ACA ATG TGT GAG AAG CAG | 1041 |
| CCG TTT CCG CTA TTA CAA AC | ||
|
| ATG ATG ACT CAG AGC ATT CGC CGC | 876 |
| TCA GAA ACC GTG GGT TAC GAT TTT | ||
|
| GTG ACA AAG AGA GTG CAA CGG | 857 |
| ATG ATT CTC GCC GCT GAA GCC | ||
|
| CAC ACG TGG AAT TTA GGG ACT | 995 |
| GCC GTC TAA GGC GAT AAA CA | ||
|
| TTC TTG AAG ACG AAA GGG C | 1150 |
| ACG CTC AGT GGA ACG AAA AC | ||
|
| CAC TCA AGG ATG TAT TGT G | 885 |
| TTA GCG TTG CCA GTG CTC G | ||
|
| ACA CAA TAC ATA TCA ACT TCG C | 813 |
| AGT GTG TTT AGA ATG GTG ATC |
Minimal inhibitory concentrations of cefalotin and ceftazidime against Escherichia coli isolates.
| MIC of | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Isolate | Antimicrobial | Parent type | -1 | -2 | -3 | -4 | -5 | -6 | -7 | -8 | -9 |
| E4 | Cefalotin† | 4 | 8 | 32 # | 80 # | 240 # | 240 # | 320 # | 320 # | 320 # | 320 # |
| Ceftazidime‡ | 0.125 | 0.25 | 2 | 4 | 16 # | 16 # | 32 # | 32 # | 64 # | 128 # | |
| E11 | Cefalotin | 0.5 | 2 | 16 | 32 # | # | # | # | # | # | # |
| Ceftazidime | 1 | 4 | 8 # | 8 # | 16 # | 32 # | 32 # | 64 | 128 # | 128 # | |
| E21 | Cefalotin | 2 | 8 | 16 | 16 | # | # | # | # | # | # |
| Ceftazidime | 0.5 | 1 | 4 | 4 | 8 # | 16 # | 16 # | 32 # | 32 # | 64 # | |
No mark: susceptible or intermediate to cefalotin or ceftazidime; #: resistant to cefalotin or ceftazidime. Breakpoints for cefalotin were as follows: susceptible ⩽ 8 μg/mL, intermediate 16 μg/mL, and resistant ⩾ 32 μg/mL. Breakpoints for ceftazidime were as follows: susceptible ⩽ 2 μg/mL, intermediate 4 μg/mL, and resistant ⩾ 8 μg/mL.
Escherichia coli isolates at various generations that were induced by cefalotin or ceftazidime.
†MIC values of cefalotin were determined for E. coli isolates induced by cefalotin.
‡MIC values of ceftazidime were determined for E. coli isolates induced by ceftazidime.
Figure 1Colony morphology of parent Escherichia coli and antibiotic-induced isolates recovered after induction (24 h). (a), (d), and (g) were parent strains; (b), (e), and (h) were cefalotin-induced isolates; and (c), (f), and (i) were ceftazidime-induced isolates.
Figure 2Cell morphology of parent Escherichia coli and isolates recovered after induction with antibiotics. Cells were subjected to Gram-staining and examined with an optical microscope (1000×). (a), (d), and (g) were parent strains; (b), (e), and (h) were cefalotin-induced isolates; and (c), (f), and (i) were ceftazidime-induced isolates.
Antimicrobial susceptibility profiles of the Escherichia coli isolates recovered after induction with cefalotin.
| Resistant | |||
|---|---|---|---|
| Antimicrobial | Derived from E4 | Derived from E11 | Derived from E21 |
| Cefoxitin | CF-3/-4/-5/-6/-7/-8/-9 | CF-5/-6/-7/-8/-9 | CF-5/-6/-7/-8/-9 |
| Ceftazidime | CF-5/-6/-7/-8/-9 | CF-5/-6/-7/-8/-9 | CF-7/-8/-9 |
| Ampicillin | CF-4/-5/-6/-7/-8/-9 | CF-3/-4/-5/-6/-7/-8/-9 | CF-6/-7/-8/-9 |
| Amoxicillin/clavulanic acid | CF-4/-5/-6/-7/-8/-9 | CF-4/-5/-6/-7/-8/-9 | CF-6/-7/-8/-9 |
| Kanamycin | CF-4/-5/-6/-7/-8/-9 | CF-7/-8/-9 | CF-6/-7/-8/-9 |
All E. coli isolates had intermediate resistance to cefoxitin, ceftazidime, and kanamycin.
Antimicrobial susceptibility profiles of the Escherichia coli isolates recovered after induction with ceftazidime.
| Resistant | |||
|---|---|---|---|
| Antimicrobial | Derived from E4 | Derived from E11 | Derived from E21 |
| Cefalotin | CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 | CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 | CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 |
| Cefoxitin | CAZ-4/-5/-6/-7/-8/-9 | CAZ-3/-4/-5/-6/-7/-8/-9 | CAZ-4/-5/-6/-7/-8/-9 |
| Ampicillin | CAZ-2/-3/-4/-5/-6/-7/-8/-9 | CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 | CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 |
| Amoxicillin/ | CAZ-2/-3/-4/-5/-6/-7/-8/-9 | CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 | CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 |
| Kanamycin | CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 | CAZ-2/-3/-4/-5/-6/-7/-8/-9 | CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 |
All E. coli isolates had intermediate resistance to kanamycin.
Figure 3Extended spectrum beta-lactamase (ESBL) production of isolates recovered after induction by cefalotin (a) or ceftazidime (b). Isolates at various generations are listed on the X-axis. Differences were calculated as diameter of the inhibition zone of ceftazidime plus clavulanic acid subtracted from their respective single discs. An isolate was designated an ESBL producer if the difference was > 5 mm.
Figure 4Endotoxin release of Escherichia coli isolates included in the study at various time points (0, 2, 4, 6, 8, and 10 h).
Results of a linear mixed regression model for log endotoxin release (log of EU/mL) by Escherichia coli after exposure to cefalotin (CF) or ceftazidime (CAZ).
| Parameter | Estimate | SEM |
|
|---|---|---|---|
| Parent isolates (Ref.) | 6.07 | 0.11 | <0.001 |
| CAZ | 0.50 | 5.01 x 10−3 | <0.001 |
| CF | 0.02 | 5.01 x 10−3 | 0.699 |
| Interactions† | |||
| CAZ x generation | 3.78 x 10−4 | 5.23 x 10−3 | 0.942 |
| CF x generation | 1.39 x 10−3 | 5.23 x 10−3 | 0.791 |
| Time (h) | 1.60 | 0.02 | <0.001 |
| Time2 (h2) | -0.16 | 5.39 x 10−3 | <0.001 |
| Time3 (h3) | 0.01 | 3.54 x 10−4 | <0.001 |
|
| |||
| Between-replicate variance | 0.03 | 0.16 | |
Endotoxin release was measured at various time points (2, 4, 6, 8, and 10 h) and resistance was induced over varying numbers of generations.
Baseline to which other samples were compared was a parent isolate (generation 0)
†Interactions were not created with the parent isolate as there was only 1 generation